From Our Partners
Friday, June 24, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Novel Antimicrobials for Killing Anthrax

by Global Biodefense Staff
June 7, 2012

The CDC’s Division of High-Consequence Pathogens and Pathology (DHCPP) Bacterial and Special Pathogens Branch this week announced its intent to issue a purchase order to the University of Michigan Life Sciences Institute for the production of novel antimicrobials for specific killing of Bacillus anthracis.

Despite the problem of bacteria becoming increasingly resistant to the current arsenal of therapeutic agents, few novel classes of antimicrobials have been discovered.  In addition to naturally acquired resistance, there is increasing concern that engineered, multi-drug resistant (MDR) strains could be used in a bioterrorism event.  According to the CDC, such an occurrence could greatly limit or eliminate their ability to effectively treat diseases such as anthrax, where early administration of appropriate antimicrobials is critical for care and a positive patient outcome.

One approach in recent years has been to use anti-sense oligonucleotides (oligos) to target specific mRNA to inhibit bacterial growth. Although the anti-sense approach has been used since the 1970s, several developments have led to more recent success. First was the development of morpholino oligos, which are resistant to ribonucleases, and thus more stable. Second was the addition of membrane-penetrating peptides to morpholino oligos in order to increase uptake and effectively kill bacteria.

The planned effort involves using morpholino oligos linked to Bacillus anthracis siderophores to treat anthrax. The siderophores bind iron and the iron-siderophore complex is then transported across the cell envelope into the cell. The siderophore would act as a “Trojan horse” and lead to the active uptake of the drug, and approach that has been used successfully with traditional antibiotics.

Work to generate a new class of antimicrobial agents will focus on generating a modified form of the virulence factor petrobactin that is covalently modified with an anti-sense morpholino oligonucleotide. The process requires the development of a method to conjugate a morpholino-oligonucleotide to the siderophore. This molecule would be recognized by receptors on the cell surface of the bacteria, and internalized where the covalently linked antisense oligonucleotide would bind to its complimentary strand of RNA blocking translation of genes necessary for growth.

Such a process could be applied as a means of killing other pathogenic bacteria and used as a therapeutic in the case of organisms with resistance to currently used antibiotics.

The contract effort is managed under Solicitation Number: 00HCVLEG-2012-43251.

From Our Partners
Tags: AnthraxAntimicrobialsBioterrorism

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC